Amid the coronavirus disease (COVID-19) pandemic, scientists and health experts race to develop drugs and vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many ...
A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with ...
Inhaled delivery of a formulation of a key protein involved in the immune response - interferon beta-1a - to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe ...
An inhaled form of interferon — a drug commonly used to treat multiple sclerosis by injection — may help protect hospitalized Covid-19 patients from getting worse, according to a British drugmaker.
Positive opinion is supported by data from more than 1,000 real-world pregnancy outcomes Data indicate no increased risk of major congenital anomalies after exposure to interferon beta before ...
Patients with clinically isolated syndromes (CIS) are prone to develop multiple sclerosis (MS). The randomized, placebo-controlled CHAMPS trial found early treatment with interferon -1a to be ...
A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with ...
Specialists in neuroimaging at UB have proposed a mechanism by which interferon beta-1a may limit brain atrophy in multiple sclerosis (MS) patients. The positive effect of interferon beta-1a, a ...
A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results